MECLOFENAMATE SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Meclofenamate Sodium, and what generic alternatives are available?
Meclofenamate Sodium is a drug marketed by Am Therap, Ani Pharms, Barr, Chartwell Rx, Mylan, Par Pharm, Usl Pharma, Vitarine, and Watson Labs. and is included in eighteen NDAs.
The generic ingredient in MECLOFENAMATE SODIUM is meclofenamate sodium. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meclofenamate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Meclofenamate Sodium
A generic version of MECLOFENAMATE SODIUM was approved as meclofenamate sodium by MYLAN on September 3rd, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MECLOFENAMATE SODIUM?
- What are the global sales for MECLOFENAMATE SODIUM?
- What is Average Wholesale Price for MECLOFENAMATE SODIUM?
Summary for MECLOFENAMATE SODIUM
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 18 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Clinical Trials: | 1 |
DailyMed Link: | MECLOFENAMATE SODIUM at DailyMed |
Recent Clinical Trials for MECLOFENAMATE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Federal University of São Paulo | Phase 4 |